Spesolimab (SPEVIGO) — TrialistMD Drug Profile TRIALISTMD · Drug Intelligence Platform FDA APPROVED 2022 IL-36R
Clinical trials
Delgocitinib
Delgocitinib (ANZUPGO) — TrialistMD Drug Profile TRIALISTMD · Drug Intelligence Platform FDA APPROVED 2025 JAK
Bimekizumab
FDA Approved · October 2023 IL-17A & F Inhibitor · Dermatology · Plaque Psoriasis âš
Difamiliast
FDA Approved · February 2026 PDE-4 Inhibitor · Dermatology · Atopic Dermatitis Difamilast ADQUEY™ ·
Deuruxolitinib
Deuruxolitinib (LEQSELVI) — TrialistMD Drug Profile TRIALISTMD · Drug Intelligence Platform FDA APPROVED 2024 JAK
NAVEPEGRITIDE
NAVEPEGRITIDE (YUVIWEL) Navepegritide (YUVIWEL) is a once-weekly subcutaneous injection designed to enhance linear growth in pediatric patients aged two and